knowledge -WSS

knowledge

author：knowledge 2025-08-21 08:27:11 - browse：27134

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Pancreatic cancer early detection could be helped by AI

hotspot

WSS

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

The PBM ad wars are taking over Washington, D.C.

Reconstructing family trees of blood cells may help predict disease

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Medicare drug price negotiation legal challenge met with skepticism

entertainment

knowledge

hotspot

In Memoriam: Notable people who died in 2023

Reconstructing family trees of blood cells may help predict disease

Supreme Court strikes down use of affirmative action

Neutralizing antibodies against HIV shows promise in children

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Wegovy leads to weight loss. Can it treat depression, too?

In Memoriam: Notable people who died in 2023

Venture capital firm's plans to take over Akron hospital face hurdles

Psychedelics group wrestles with new pharma identity

Merck CEO won’t testify in Senate, citing no expertise in drug prices

hotspot

Trump seeks lengthy delay of classified docs trial, citing upcoming election

Venture capital firm's plans to take over Akron hospital face hurdles

FTC sues over Novant Health acquisition of two N.C. hospitals

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Trump seeks lengthy delay of classified docs trial, citing upcoming election

Medicare Advantage insurers face 0.2% cut to 2025 payments

leisure time

Wikipedia

hotspot

explore